secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-08-20T11:04:58+00:00
Accession:  0001437749-26-028590
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen secures exclusive option to license IntraGel's TumoCure for head and neck cancer; invests up to $7M
--------------------------------------------------------------------------------

- On Aug 18, 2026, UroGen U.S. entered an Option and Research License Agreement with IntraGel Therapeutics for TumoCure (head and neck cancer).
- UroGen obtained exclusive option for worldwide license to develop/commercialize TumoCure using IntraGel's SRGel biodegradable hydrogel platform.
- Also obtained options for additional SRGel-based products with UroGen-designated compounds, plus non-exclusive research license.
- UroGen agreed to invest up to $7,000,000 in IntraGel equity via Securities Purchase Agreement on same date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/0001437749-26-028590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926028590/urgn20260819_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer